TSLP rs183725: What Your Genotype Means
The rs183725 variant (closely linked to the well-studied TSLP promoter polymorphism rs1837253) is located upstream of the thymic stromal lymphopoietin (TSLP) gene on chromosome 5q22.1. Research associates this regulatory region with modulation of TSLP cytokine production in epithelial barrier tissues, thereby altering statistical susceptibility to allergic sensitization, childhood asthma, and food allergy. Carried commonly across diverse global ancestries, its alleles show modest shifts in complex atopic disease risk rather than deterministic clinical outcomes.
What each genotype means
Typical TSLP expression profile
This genotype represents the common form of the TSLP promoter region. Research suggests this variant is associated with susceptibility to allergic conditions, though individual risk is influenced by a complex interplay of environmental factors and other genetic markers. Please consult with a healthcare provider to discuss your personal health history and any concerns regarding allergic sensitization.
This is the most common genotype in many populations, though frequencies vary significantly by ancestry.
Altered TSLP expression profile
Carrying one copy of the T allele may influence the expression levels of the TSLP cytokine, which plays a role in allergic inflammation. Studies have linked variants in this region to susceptibility for asthma and allergic sensitization, but the clinical impact is highly variable between individuals. This finding should be interpreted in the context of your overall health and family history by a medical professional.
This heterozygous genotype is found in a significant portion of European and East Asian populations, reflecting the common nature of this variant.
Increased TSLP expression profile
This genotype is associated with variations in the TSLP promoter that may alter the regulation of immune responses related to allergic disease. While some research identifies this variant as a susceptibility locus for asthma and food allergies, it is not a diagnostic marker and does not guarantee the development of any condition. Discuss your clinical history and any symptoms with your doctor to determine if further evaluation is appropriate.
This genotype is less common than the CC or CT configurations, appearing in a smaller subset of the population across studied ancestries.
Genetic Architecture and Location of the Variant
The single nucleotide polymorphism cataloged under rs183725 sits in the 5' flanking regulatory region of the TSLP gene on chromosome 5q22.1. This genomic area contains a dense cluster of immune-modulating cytokines. Rather than coding for an amino acid substitution, rs183725 resides in a regulatory promoter and enhancer domain, a region enriched with transcription factor binding motifs and histone modifications. Within genetic studies, rs183725 is located within a strong linkage disequilibrium (LD) block alongside other regulatory variants, most notably the extensively characterized promoter variant rs1837253. Because variants in this promoter region are inherited together in high linkage, functional changes in chromatin accessibility and transcriptional initiation are attributed to the shared haplotype. Mutations or natural polymorphisms in non-coding promoters frequently influence how readily cellular machinery transcribes RNA, directly modulating how much protein a cell produces in response to environmental triggers without altering the protein's core structural sequence.
The Biological Function of TSLP as an Epithelial Alarmin
The TSLP gene encodes thymic stromal lymphopoietin, an epithelial-derived cytokine that operates as a critical 'alarmin' at barrier surfaces such as the respiratory airway lining, skin epidermis, and gastrointestinal mucosa. When epithelial cells encounter environmental challenges—including airborne allergens, viral double-stranded RNA, or mechanical damage—they release TSLP. The cytokine signals through a heterodimeric receptor complex consisting of the TSLP receptor (TSLPR) and the interleukin-7 receptor alpha chain (IL-7Rα). Activation of this pathway predominantly primes CD11c-positive dendritic cells and group 2 innate lymphoid cells (ILC2s), stimulating the downstream release of classic type 2 cytokines such as IL-4, IL-5, and IL-13. This immune cascade drives eosinophil maturation, mucus hypersecretion, and immunoglobulin E (IgE) synthesis. Because TSLP serves as an upstream gatekeeper of the allergic response, subtle variations in its baseline or stimulated expression can meaningfully shift the threshold for atopic inflammation.
Evidence for Association with Asthma and Allergic Sensitization
Multiple genome-wide association studies (GWAS) and candidate gene analyses have evaluated the TSLP promoter locus in relation to atopic diseases, including childhood eosinophilic asthma, allergic rhinitis, and food allergy. Published literature indicates that the minor allele in this promoter region (typically evaluated as the T allele at rs1837253 / rs183725) is associated with reduced TSLP protein secretion from primary nasal epithelial cells following viral or microbial stimulation. Clinically, this attenuated secretion correlates with a modest, statistically significant protective effect against bronchial asthma and atopic sensitization. However, the evidence strength for rs183725 itself remains classified as limited to moderate. Complex traits like asthma are heavily polygenic, driven by hundreds of subtle genetic variants interacting with environmental exposures, tobacco smoke, and viral infections. Furthermore, epistatic interactions—such as combined effects with epithelial barrier genes like SPINK5 or FLG—demonstrate that this variant acts as an incremental modifier rather than a primary driver.
Ancestry and Global Population Frequencies
The rs183725 variant is a common human polymorphism rather than a rare pathogenic mutation. According to population genetics catalogs, the minor allele frequency (MAF) consistently ranges between approximately 0.20 and 0.30 in populations of European and East Asian ancestry. Significant allele frequency differences and varying degrees of linkage disequilibrium exist across distinct global populations; for instance, African-descent cohorts frequently display shorter linkage blocks across 5q22.1, meaning that associations observed in European cohorts do not always replicate with identical effect sizes in admixed or African populations. Because the variant exists at substantial frequencies worldwide, it represents common ancestral diversity. Having one or two copies of either allele is standard within the human genome and reflects common evolutionary balance within mucosal immune pathways rather than an uncommon health defect.
Clinical Utility and Lifestyle Interpretations
Genotype findings at rs183725 provide educational insight into biological predisposition, but they have no standalone diagnostic or direct therapeutic utility. Carrying an allele linked to higher or lower TSLP promoter activity does not guarantee the development—or prevention—of asthma, eczema, or food allergies. While modern medicine has developed targeted biologic therapies against TSLP, such as monoclonal antibodies approved for severe asthma, clinical prescribing is dictated entirely by clinical phenotype, symptom severity, and biomarker counts, never by single SNP genotyping. Individuals should not alter any asthma maintenance inhalers, dietary choices, or allergy avoidance protocols based on consumer genetic tests. Any concerns regarding respiratory symptoms, recurrent wheezing, or suspected allergic reactions should always be discussed directly with an allergist, pulmonologist, or primary healthcare provider.
How common is this variant?
The minor allele frequency for rs183725 and its linked promoter variants generally spans 0.20 to 0.30 across European and East Asian ancestral groups, while displaying variable frequencies and altered linkage disequilibrium structures in African populations.
Frequently asked questions
Does having the rs183725 risk genotype mean I will develop asthma?
No, it does not. The variant provides only a minor statistical influence on TSLP expression, and asthma is an inherently complex condition shaped by environmental triggers, viral exposures, and dozens of other genetic factors.
Can rs183725 determine if I need anti-TSLP biologic medication?
No. Decisions regarding biologic therapies for severe asthma depend strictly on clinical symptom control, eosinophil levels, and physician evaluation. DNA testing for this variant is not approved or used for guiding medical treatment.
Why is this variant classified as having limited evidence?
While the biological role of the TSLP promoter is well-established, effect sizes vary considerably across different ancestral cohorts, and rs183725 often functions within complex haplotypes and gene-environment interactions rather than acting as an independent causal factor.
What is the biological difference between TSLP alleles?
Laboratory assays show that alleles at this promoter locus alter transcription factor binding, which can dampen or enhance the amount of TSLP alarmin cytokine released by airway epithelial cells when challenged by allergens or viruses.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs183725?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TSLP
A promoter variant regulating thymic stromal lymphopoietin expression, thereby controlling dendritic cell priming and eosinophilic allergic responses.
Upstream variant of thymic stromal lymphopoietin linked to elevated eosinophil activation and susceptibility to allergic disease.
A well-characterized intergenic polymorphism upstream of TSLP conferring increased risk of eczema-associated food allergy and allergic eosinophilic airway disease.
Functional TSLP locus variant associated with circulating TSLP levels and predisposition to eosinophilic inflammation and asthma.
Upstream variant that alters thymic stromal lymphopoietin expression, increasing susceptibility to eosinophilic inflammation and food allergy.
Intergenic/promoter region SNP upstream of TSLP that strongly associates with eosinophilic esophagitis, asthma, atopic dermatitis, and allergic sensitization phenotypes.